Covered grower — debt is the watch. A 2.3% yield from $2.52 a quarter is covered on a non-GAAP basis — $10.08 a year is about 44% of guided 2026 non-GAAP EPS — and free cash flow covered it in the first half. The watch is the balance sheet behind it: $57.3 billion of debt at June 30, 2026, much of it taken on for the Horizon deal, and trailing GAAP coverage is fuller at 62.6%.
Key risk: Debt taken on for the Horizon deal — $57.3 billion outstanding at June 30, 2026 against $14.0 billion in cash — claims cash alongside the dividend, at the same time biosimilar pressure cut Prolia and Xgeva combined sales 33% in Q2 2026. If growth drivers stop offsetting that erosion, debt service, capex and R&D compete directly with dividend growth.
Changes if: The December raise is skipped or cut back, the payout pushes well past about 52% of free cash flow, or debt stops falling. On the non-GAAP basis the dividend is covered today; a fuller GAAP or cash payout with no deleveraging would change that read.
- !Payout-coverage check: 44.0% of guided non-GAAP EPS — $10.08 against the $22.30–$23.50 guide for 2026 — but 62.6% of trailing GAAP earnings and about 52% of free cash flow in the year to June 30, 2026. Covered on the adjusted basis; fuller on GAAP and cash, with $57.3B of debt at June 30, 2026.
- ✓Yield check: 2.3% indicated — $2.52/qtr × 4 at the $439.26 close on Oct. 23, 2026. Real, earned yield for a single stock, not a special or a return of capital.
- ✓Dividend growth check: 15 years of increases; the latest raise, declared Dec. 9, 2025, lifted the quarterly dividend 5.9%, from $2.38 to $2.52. Raises have run annually in December.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.